Showing results (1641-1650 of 1,662) with videos related to
Sort By:
Pageof 167
Journal of Medicinal Chemistry|June 5, 2025
Validation, Key Pharmacophores, and X-ray Cocrystal Structures of Novel Biochemically and Cellularly Active WRN Inhibitors Derived from a DNA-Encoded Library ScreenYunsong Tong, Kenton A Baker, Alex M Chapman, et al.Genomics|June 20, 2024
Identification of prognostic biomarkers for cholangiocarcinoma by combined analysis of molecular characteristics of clinical MVI subtypes and molecular subtypesMing-Yue Li, Ya-Hui Liu, Feng Wei, et al.Nature|April 3, 2010
N-myristoyltransferase inhibitors as new leads to treat sleeping sicknessJulie A Frearson, Stephen Brand, Stuart P McElroy, et al.Molecular Cancer Therapeutics|March 20, 2024
Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell LymphomaJoshua P Plotnik, Adam E Richardson, Haopeng Yang, et al.Science Advances|February 1, 2021
Gut microbiota from patients with arteriosclerotic CSVD induces higher IL-17A production in neutrophils via activating RORγtWei Cai, Xiaodong Chen, Xuejiao Men, et al.Journal of Clinical Pharmacology|April 2, 2008
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance processShiew-Mei Huang, John M Strong, Lei Zhang, et al.Science Translational Medicine|March 20, 2024
An anti-TNF-glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseasesMichael J McPherson, Adrian D Hobson, Axel Hernandez, et al.Frontiers in Neurology|April 27, 2026
Impact of hospital process reengineering on door-to-needle time for intravenous thrombolysis in acute ischemic stroke (PROMISE-CHINA): a multicenter prospective pre-post quasi-experimental studyDawei Dong, Longyan Lu, Niu He, et al.Journal of Medicinal Chemistry|September 16, 2024
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase InhibitorYiyun Yu, Miyeon Jang, Julie Miyashiro, et al.Nature|September 28, 2017
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.Pageof 167